References
1. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. Predictors of the severity and serious outcomes of anaphylaxis in Korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015; 7:22–29.
2. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009; 123:434–442.
3. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, et al. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008; 100:31–36.
4. Park HK, Kang MG, Yang MS, Jung JW, Cho SH, Kang HR. Epidemiology of drug-induced anaphylaxis in a tertiary hospital in Korea. Allergol Int. 2017; 66:557–562.
5. Ribeiro-Vaz I, Marques J, Demoly P, Polónia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol. 2013; 69:673–681.
6. Zhao Y, Sun S, Li X, Ma X, Tang H, Sun L, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database. Int J Clin Pharm. 2018; 40:1349–1358.
7. Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, et al. Drug-induced anaphylaxis in a Vietnamese Pharmacovigilance Database: trends and specific signals from a disproportionality analysis. Drug Saf. 2019; 42:671–682.
8. Cho MK, Moon M, Kim HH, Kang DY, Lee JY, Cho SH, Kang HR. Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System. Allergy Asthma Respir Dis. 2020; 8:30–35.